You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Health Care Service Corporation and New York's Excellus BlueCross BlueShield will begin covering the test as medically necessary for its members.
Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.
Cancer Genetics will provide oncology testing services to Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield Nebraska, and WellMark.
While the overall number of oncologists who ordered the company's tests in the third quarter did not change, the frequency with which they reordered fell by about 7 percent.
The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.
The plan will cover the gene expression test for prostate cancer aggressiveness for all men with localized disease.
Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.
Discovery's clients will be able to receive genomic sequencing services, including exome sequencing and analysis for $250 through its Vitality program.
The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.
The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.
In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.
According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.